louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02402413: Ultrasound Three-dimensional Characterization of Ovarian Morphology in Women With Polycystic Ovary Syndrome (PCOS)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: PCOS
Hyperandrogenism
Lead sponsor: University of Cagliari
Sponsor class: OTHER
First posted: 2015-03-30
Enrollment: 100
Sex: FEMALE
Minimum age (years): 15
Maximum age (years): 25
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: Polycystic ovary syndrome (PCOS) is one of the most common endocrine disorders occurring in women of reproductive age. PCOS is considered a syndrome of ovarian dysfunction that is characterized by the heterogeneous clinical manifestation of infrequent or absent menstrual cycles, hyperandrogenism, and polycystic ovarian morphology.

An important ultrasound parameter is the ratio stroma/ovary, the ratio of the volume, evaluated in two-dimensional ultrasound, of the stroma, that secrete androgen, and the ovary. It has been shown that when this ratio is higher than a third the levels of circulating androgens and high. Aim of the present study is to assess whether this ratio, determined with three-dimensional ultrasound, is correlated to the increase of androgens.


Eligibility criteria: Inclusion Criteria:

* Self-reported history of infrequent or absent menstrual cycles and/or PCOS ultrasound feature and/or clinical or biochemical hyperandrogenism
* Did not take hormonal contraception, fertility therapies, or insulin sensitizers in the three months prior to enrollment

Exclusion Criteria:

* Pregnancy

Primary outcomes:
measure: Androgens serum levels in women with ultrasound morphological PCO
timeFrame: up to 1 year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Fulghesu AM, Ciampelli M, Belosi C, Apa R, Pavone V, Lanzone A. A new ultrasound criterion for the diagnosis of polycystic ovary syndrome: the ovarian stroma/total area ratio. Fertil Steril. 2001 Aug;76(2):326-31. doi: 10.1016/s0015-0282(01)01919-7.
Clinical trial NCT00150813: Monotherapy With Levetiracetam in Patients Suffering From Epilepsy.
Official title: A Multicenter, Open-label, Follow-up Trial Evaluating the Long-term Safety of Levetiracetam Individualized Dose From 1000 to 3000 mg/Day (Oral Tablets of 500 mg b.i.d.), Used as Monotherapy in Subjects (≥ 16 Years) Suffering From Epilepsy and Coming From the N01061 or the N01093 Trials.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Epilepsy, Tonic-clonic
Keywords: Monotherapy
Epilepsy
Keppra
Levetiracetam
Lead sponsor: UCB Pharma
Sponsor class: INDUSTRY
First posted: 2005-09-08
Enrollment: 66
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: An open-label follow-up trial assessing the long term safety of levetiracetam as per adverse events reporting.


Eligibility criteria: Inclusion Criteria:

* Subjects with a confirmed diagnosis of epilepsy.
* Subjects having experienced in the past unprovoked partial seizures (IA, IB, IC with clear focal origin),or generalized tonic-clonic seizures (without clear focal origin), that are classifiable according to the International Classification of Epileptic Seizures
* Subjects having participated in the previous double-blind monotherapy trial (N01061 \[NCT00150735\] or N01093 \[NCT00150787\]).
* Male/female subjects (\>= 16 years).

Exclusion Criteria:

- Need for an additional Antiepileptic Drug (AED).

Primary outcomes:
measure: Percentage Participants With Treatment Emergent Adverse Events
timeFrame: From the Entry Visit until up to 2 weeks after the last drug intake, up to 93 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Beroun
country: Czechia
city: Brno
country: Czechia
city: Ceske Budejovice
country: Czechia
city: Praha 1
country: Czechia
city: Praha 5
country: Czechia
city: Rychnov nad Kneznou
country: Czechia
city: Budapest
country: Hungary
city: Debrecen
country: Hungary
city: Pécs
country: Hungary
city: Szeged
country: Hungary
city: Białystok
country: Poland
city: Gdańsk
country: Poland
city: Katowice
country: Poland
city: Lublin
country: Poland
city: Szczecin
country: Poland
city: Warszawa
country: Poland
city: Łódź
country: Poland
city: Göteborg
country: Sweden
city: Helsingborg
country: Sweden
city: Huddinge
country: Sweden
city: Karlstad
country: Sweden
city: Uppsala
country: Sweden
Study officials:
affiliation: 001 844 599 2273 (UCB)
name: UCB Cares
role: STUDY_DIRECTOR
References:
Clinical trial NCT05307913: PET - PEEP by EIT for Acute Respiratory Distress Syndrome Trial
Official title: EIT-guided PEEP Titration Versus Low PEEP/FiO2 Table for ARDS: a Multicenter, Randomized, Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: ARDS, Human
Keywords: electrical impedance tomography
ARDS
PEEP
Lead sponsor: Peking Union Medical College Hospital
Sponsor class: OTHER
First posted: 2022-04-01
Enrollment: 680
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is a multicentric randomized controlled study.The objective of this study is to compare the prognosis of patients with ARDS between EIT-oriented individualized PEEP and traditional lower PEEP/FiO2 table-oriented PEEP strategy.


Eligibility criteria: Inclusion Criteria:

Intubated, mechanically ventilated patients with diagnosis of ARDS according to ARDS Berlin standard by attending doctor

Exclusion Criteria:

1. Age \< 18 years old and \> 90 years old;
2. Pregnancy;
3. EIT contradictions (presence of pacemaker or automatic implantable cardioverter defibrillator);
4. Severe intracranial hypertension;
5. Pneumothorax, pneumomediastinum, subcutaneous emphysema or at high-risk for pneumothorax (e.g., pneumatocele, interstitial lung disease);
6. Unstable hemodynamic status intorerable to lung recruitment and PEEP titration, judged by an attending intensivist; (This may be a transient criterion, since patients meeting this criterion might be included later if hemodynamics improves)
7. End status of disease;
8. Patients or their families refused to participate in the study

Primary outcomes:
measure: Survival in 28 days
timeFrame: 28 days
Secondary outcomes:
measure: Lenght of ICU stay
timeFrame: Maximum 6-months
measure: Lenght of hospital stay
timeFrame: Maximum 6-months
measure: 28-day ventilator-free days
timeFrame: 28 days
measure: Barotrauma
timeFrame: 7 days
measure: ICU survival
timeFrame: Maximum 6-months
measure: hospital survival
timeFrame: Maximum 6-months
measure: change of Sequential Organ Failure Assessment (SOFA) score
timeFrame: 2 days
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking Union Medical College Hospital
state: Beijing
Study officials:
References:
Clinical trial NCT05769413: Awareness of Osteoporosis in HIV Patients
Official title: Awareness of Osteoporosis in HIV Patients
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Human Immunodeficiency Virus Infection
Osteoporosis
Osteoporosis Risk
Lead sponsor: Uskudar State Hospital
Sponsor class: OTHER_GOV
First posted: 2023-03-15
Enrollment: 400
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients aged 18 to 90 years with human immunodeficiency virus infection who gave consent to participate in the study.

Brief summary: Osteoporosis is a condition that describes compromised skeletal microarchitecture in general, with clinical signs of decreased bone mineral density. Patients with human immunodeficiency virus infection are at increased risk for developing osteoporosis. Identifying whether patients with human immunodeficiency virus infection have information and awareness about this disease is crucial. This study is aimed to investigate awareness and knowledge of osteoporosis in patients with human immunodeficiency virus infection.

Detailed description: Osteoporosis is a common disease of bone loss. The reduced bone strength predisposes an increased risk for fractures in older individuals. It can affect people from different ethnicity. Many factors increase the risk of osteoporosis, including age, postmenopausal state, glucocorticoid use, low body weight, calcium, vitamin D, immobility, and chronic inflammation. Patients with human immunodeficiency virus infection are at high risk of developing osteoporosis due to chronic inflammation and their medications. Patients' knowledge and awareness about osteoporosis are essential for early detection, implementation of lifestyle changes, and treatment compliance. This study aimed to investigate osteoporosis awareness and knowledge about osteoporosis in patients with human immunodeficiency virus infection.

Eligibility criteria: Inclusion Criteria:

* Clinical diagnosis of human immunodeficiency virus
* Must be between the ages of 18 and 99
* Must give consent to participate in the study

Exclusion Criteria:

• Not giving consent

Primary outcomes:
measure: Revised Osteoporosis Knowledge Test
timeFrame: 1 day
Secondary outcomes:
measure: Osteoporosis Self-Efficacy Scale
timeFrame: 1 day
measure: Osteoporosis Health Belief Scale
timeFrame: 1 day
Other outcomes:
Locations:
Study officials:
affiliation: Uskudar State Hospital
name: Mustafa H Temel, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04495413: Assessment of the Effect of Age on Duration of Analgesia From Single-shot Femoral Nerve Blocks
Official title: Assessment of the Effect of Age on Duration of Analgesia From Single-shot Femoral Nerve Blocks
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Analgesia
Lead sponsor: University of Washington
Sponsor class: OTHER
First posted: 2020-07-31
Enrollment: 100
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Adult ambulatory surgery patients receiving a single-shot peripheral femoral nerve block preoperatively as part of their clinical anesthesia care on day-of-surgery.

Brief summary: Cohort study to examine the effect of age on duration of analgesia in patients receiving single-shot femoral nerve block prior to surgery, by postoperative phone follow-up questionnaire.

Detailed description: The purpose of this study is to find out how differences in age can affect the duration of pain relief from a femoral nerve block. Complete recovery after leg surgery involves healing of tissues at the surgical site, recovery of muscle strength and range-of-motion. Some pain is normally experienced after leg surgery. At the hospital, pain is usually treated with pain medicines, and/or a nerve block procedure. A nerve block involves injecting a local anesthetic beside the nerves to numb the nerves that supply feeling to the knee joint and surrounding tissues. The choice as to whether a participant has a nerve block or not is made by the participant and their surgeon and is not determined by this research study. The study aim is to find out how long a nerve block can relieve postsurgical pain, and whether that duration is affected by the age of the participant.

Eligibility criteria: Inclusion Criteria:

* Adult patients (age \>18 years)
* American Society of Anesthesiology physical status 1-3
* Having ambulatory surgery, who have received a single-shot femoral nerve block
* Able to read and understand English
* Have access to a phone after surgery

Exclusion Criteria:

* Pediatric patients (age \<18 years)
* American Society of Anesthesiology physical status \>3
* Unable to read and understand English
* Unable to have access to a phone after surgery

Primary outcomes:
measure: Duration of analgesia
timeFrame: From time of block placement to patient to the reported end of analgesic effect, up to 72 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Seattle
country: United States
facility: University of Washington Medical Center
state: Washington
Study officials:
affiliation: University of Washington
name: Vanessa J Loland, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03732313: Altering Toenail Biomechanic in Managing Ingrown Toenail.
Official title: Altering Toenail Biomechanic in Managing Ingrown Toenail.Randomized Clinical Trial.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Ingrown Toenail
Keywords: Ingrown toenail
Biomechanic
Central resection
Recurrence
Lead sponsor: Zagazig University
Sponsor class: OTHER_GOV
First posted: 2018-11-06
Enrollment: 10
Sex: ALL
Minimum age (years): 10
Maximum age (years): 35
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Ingrown toenail is commonly met in clinical practice.treatment may be non-operative and operative treatment.operative trestment depends on lateral wedge resection of the nail. The idea is to change toenail biomechanics by central toenail resection.

Detailed description: The aim of this study is to compare between central toenail resection with ordinary lateral wedge resection in managing ingrown toenail. This study was performed on 100 patients divided into 2 groupd each is 50 patients. Group A underwent central resection while group B underwent lateral toenail resection.

Eligibility criteria: Inclusion Criteria:

* patient with ingrown toenail
* Patients from 10 years up to 35 years

Exclusion Criteria:

* patients with concurrent toe deformity
* patients less than 10 years or more than 35 years

Primary outcomes:
measure: Postoperative pain on visual analog score for pain
timeFrame: six month
measure: Intraoperative time measured in minutes
timeFrame: Six month
Secondary outcomes:
measure: Recurrence after operation
timeFrame: six month
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01690013: Life Quality and Health in Patients With Klinefelter Syndrome
Official title: Life Quality and Health in Patients With Klinefelter Syndrome - a Questionnaire Survey
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Klinefelter Syndrome
Quality of Life
Physical Disorders
Mental Disorders
Lead sponsor: University of Aarhus
Sponsor class: OTHER
Collaborators: name: Aarhus University Hospital
First posted: 2012-09-21
Enrollment: 452
Sex: MALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Klinefelter patients is recruited from endocrinology, genetics and fertility clinics in Denmark.

An age-, educational, and zipcode-matched control group was created from Statistics Denmark by extracting five randomly selected men for each KS subject

Brief summary: Klinefelter syndrome is the most common sex-chromosome disorder in men with a prevalence of 1 in 660 men. The syndrome is associated with hypogonadism. Many patients with Klinefelter syndrome have psychological complaints and physical discomfort. Some patients report a positive effect of testosterone treatment, whereas others do not.

The aim of this study is:

(i) To investigate quality of life in patients with Klinefelter syndrome. (ii) To investigate functional, physical and mental health in patients with Klinefelter syndrome.

Questionnaire concerning mental and physical health and life quality are sent out to patients with KS and to age-, educational- and zipcode-matched men from the general population. The questionnaire include questions about housing, income, marital status, fatherhood, medication, chronic disease,school and education, attachment to the labor, sexual and erectile function, life quality, mental and physical health, satisfaction with life and symptoms of attention deficits hyperactivity disorders.


Eligibility criteria: For the Klinefelter group:

Inclusion Criteria:

* Verified Klinefelter syndrome

Exclusion Criteria:

* none

For the control group:

Inclusion Criteria:

* age-,educational,and residence-matched

Exclusion Criteria:

* none

Primary outcomes:
measure: Quality of life
timeFrame: 3 month
measure: Satisfaction with life
timeFrame: 3 month
measure: ADHD symptoms
timeFrame: 3 month
measure: General health
timeFrame: 3 month
measure: Erectile function
timeFrame: 3 month
Secondary outcomes:
Other outcomes:
measure: Housing
timeFrame: 3 month
measure: Fatherhood
timeFrame: 3 month
measure: School and educational
timeFrame: 3 month
measure: Income
timeFrame: 3 month
measure: Attachment to the labor
timeFrame: 3 month
measure: Marital status
timeFrame: 3 month
measure: Medication
timeFrame: 3 month
measure: Chronic disease
timeFrame: 3 month
Locations:
city: Aarhus
country: Denmark
facility: Medical Department M, Aarhus Universityhospital
Study officials:
affiliation: Medical Department M, Aarhus Universityhospital, Aarhus
name: Claus H Gravholt, MD, Dr.med.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01748513: Volume-challenge in Morbid Obesity
Official title: Morbid Obesity and Optimization of Preoperative Fluid Therapy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Anomaly; Venous Return
Keywords: morbidly obese patients,
preoperative volume-challenge,
transthoracic echocardiography,
TTE,
rapid weight loss,
venous return,
bariatric surgery,
left ventricular outflow tract,
stroke volume,
diastolic function,
hypervolemia,
hypovolemia
Lead sponsor: Umeå University
Sponsor class: OTHER
First posted: 2012-12-12
Enrollment: 34
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CROSSOVER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Morbidly obese patients scheduled for bariatric surgery in Northern part of Sweden; Norrbotten county council.

Brief summary: Preoperative venous return stability and euvolemia is essential in management of morbidly obese patients. Fluid therapy regimes for patients with high BMI, especially with focus on preoperative management, are rare and not in consensus.The aim of this study was to evaluate preoperative effects of a standardized, ideal body weight (IBW) based volume-challenge on hemodynamics, stroke volume and level of venous return to the heart.

Detailed description: 34 morbidly obese patients scheduled for bariatric surgery underwent a preoperative three-week preparation by rapid-weight-loss-diet (RWL) to be accepted for bariatric surgery. Preoperative transthoracic echocardiography (TTE) was performed in the awake state before and after volume-challenge (VC) based on 6ml colloids /kg IBW. Feasibility of standardized VC was evaluated by TTE. Dynamic and non-dynamic echocardiographic indices for VC were studied.

Main outcome measures: Volume-responsiveness and level of venous return before and after volume-challenge were assessed by TTE. An increase of stroke volume ≥ 13% was considered as a volume-responder.

Eligibility criteria: Inclusion Criteria:

* enrolled for bariatric surgery
* BMI ≥ 40 or ≥ 35kg/m2 with co-morbidities
* preoperative three-weeks preparation by rapid-weight-loss-diet and weight loss

Exclusion Criteria:

* untreated significant hypertension
* unstable angina pectoris
* significant valve regurgitation or stenosis
* known severe pulmonary disease

Primary outcomes:
measure: level of venous return
timeFrame: 0,1 hour
Secondary outcomes:
measure: Volume-responsiveness
timeFrame: 0,1 hour
Other outcomes:
measure: Evaluation of feasibility of dynamic and non-dynamic echocardiographic indices for volume challenge
timeFrame: 1 hour
Locations:
city: Lulea
country: Sweden
facility: Sunderby county hospital
state: Norrbotten
Study officials:
affiliation: Norrbotten county council, Umeå University
name: Tomi P Pösö, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06033313: Effects of Framing on Medication Beliefs, Intentions to Take Medication, Adherence, and Asthma Control
Official title: Examining the Effect of Message Framing on Medication Beliefs, Intentions to Take Medications, Adherence to Medication, and Asthma Control Among College Students
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Asthma
Keywords: mHealth
message framing
Lead sponsor: Auburn University
Sponsor class: OTHER
First posted: 2023-09-13
Enrollment: 43
Sex: ALL
Minimum age (years): 18
Maximum age (years): 29
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The goal of this study is to examine the effects of framed mobile messages on young adults' beliefs about their daily Inhaled Corticosteroids (ICS), intentions to take their ICS, adherence, and asthma control. College students (18-29 years) who owned a mobile phone and had a diagnosis of asthma with a prescription for an ICS will be recruited. Participants will be randomized to receive either gain- or loss-framed mobile messages three times per week for eight weeks. Outcomes including beliefs, intentions, adherence, and asthma control will be assessed.


Eligibility criteria: Inclusion Criteria:

* A diagnosis of asthma
* A prescription for an inhaled corticosteroid
* Enrolled in college
* Between 18-29 years of age
* Owns a mobile phone

Exclusion Criteria:

* Cannot read in english

Primary outcomes:
measure: Changes in Asthma control
timeFrame: Data collection at baseline, week 4, and week 8
Secondary outcomes:
measure: Changes in Medication Beliefs
timeFrame: Data collection at baseline and week 8
measure: Intentions to take medication as prescribed
timeFrame: Data collection at baseline and week 8
measure: Changes in Medication adherence
timeFrame: Data collection at baseline, week 4, and week 8
Other outcomes:
Locations:
city: Auburn
country: United States
facility: Auburn University
state: Alabama
Study officials:
References: